Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. more
Time Frame | XNCR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.06% | -2.06% | -0.55% |
1-Month Return | 2.33% | -1.92% | 2.72% |
3-Month Return | 13.81% | -10.4% | 7.66% |
6-Month Return | 22.07% | -4.6% | 10.15% |
1-Year Return | 15.36% | 4.06% | 27.53% |
3-Year Return | -39.17% | 1.94% | 32.31% |
5-Year Return | -38.09% | 36.48% | 89.2% |
10-Year Return | 45.58% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 156.70M | 122.69M | 275.11M | 164.58M | 168.34M | [{"date":"2019-12-31","value":56.96,"profit":true},{"date":"2020-12-31","value":44.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":61.19,"profit":true}] |
Cost of Revenue | 118.59M | 169.80M | 7.49M | 8.80M | 253.60M | [{"date":"2019-12-31","value":46.76,"profit":true},{"date":"2020-12-31","value":66.96,"profit":true},{"date":"2021-12-31","value":2.95,"profit":true},{"date":"2022-12-31","value":3.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 38.11M | 122.69M | 275.11M | 164.58M | (85.26M) | [{"date":"2019-12-31","value":13.85,"profit":true},{"date":"2020-12-31","value":44.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.82,"profit":true},{"date":"2023-12-31","value":-30.99,"profit":false}] |
Gross Margin | 24.32% | 100.00% | 100.00% | 100.00% | (50.65%) | [{"date":"2019-12-31","value":24.32,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-50.65,"profit":false}] |
Operating Expenses | 142.88M | 199.49M | 231.34M | 247.05M | 306.98M | [{"date":"2019-12-31","value":46.54,"profit":true},{"date":"2020-12-31","value":64.99,"profit":true},{"date":"2021-12-31","value":75.36,"profit":true},{"date":"2022-12-31","value":80.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 9.53M | (76.80M) | 43.77M | (82.47M) | (138.64M) | [{"date":"2019-12-31","value":21.77,"profit":true},{"date":"2020-12-31","value":-175.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-188.44,"profit":false},{"date":"2023-12-31","value":-316.77,"profit":false}] |
Total Non-Operating Income/Expense | 31.28M | 14.73M | 39.71M | 32.78M | 31.94M | [{"date":"2019-12-31","value":78.77,"profit":true},{"date":"2020-12-31","value":37.09,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.55,"profit":true},{"date":"2023-12-31","value":80.43,"profit":true}] |
Pre-Tax Income | 27.19M | (69.33M) | 82.63M | (54.51M) | (120.44M) | [{"date":"2019-12-31","value":32.9,"profit":true},{"date":"2020-12-31","value":-83.91,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-65.97,"profit":false},{"date":"2023-12-31","value":-145.76,"profit":false}] |
Income Taxes | 312.00K | (5.79M) | (7.49M) | 673.00K | 5.81M | [{"date":"2019-12-31","value":5.37,"profit":true},{"date":"2020-12-31","value":-99.71,"profit":false},{"date":"2021-12-31","value":-128.91,"profit":false},{"date":"2022-12-31","value":11.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | 26.88M | (63.54M) | 90.12M | (55.18M) | (126.25M) | [{"date":"2019-12-31","value":29.82,"profit":true},{"date":"2020-12-31","value":-70.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-61.23,"profit":false},{"date":"2023-12-31","value":-140.09,"profit":false}] |
Income From Continuous Operations | 26.88M | (69.33M) | 82.63M | (55.18M) | (119.03M) | [{"date":"2019-12-31","value":32.52,"profit":true},{"date":"2020-12-31","value":-83.91,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-144.05,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 26.88M | (63.54M) | 82.63M | (55.18M) | (126.09M) | [{"date":"2019-12-31","value":32.52,"profit":true},{"date":"2020-12-31","value":-76.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-66.78,"profit":false},{"date":"2023-12-31","value":-152.59,"profit":false}] |
EPS (Diluted) | 0.45 | (1.21) | 1.35 | (0.93) | (2.10) | [{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":-89.63,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-68.89,"profit":false},{"date":"2023-12-31","value":-155.56,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
XNCR | |
---|---|
Cash Ratio | 5.05 |
Current Ratio | 6.23 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
XNCR | |
---|---|
ROA (LTM) | -15.24% |
ROE (LTM) | -29.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
XNCR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
XNCR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 19.50 |
P/B | 2.42 |
Price/FCF | NM |
EV/R | 15.22 |
EV/Ebitda | NM |
PEG | NM |
Xencor Inc (XNCR) share price today is $23.73
Yes, Indians can buy shares of Xencor Inc (XNCR) on Vested. To buy Xencor Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XNCR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Xencor Inc (XNCR) via the Vested app. You can start investing in Xencor Inc (XNCR) with a minimum investment of $1.
You can invest in shares of Xencor Inc (XNCR) via Vested in three simple steps:
The 52-week high price of Xencor Inc (XNCR) is $27.24. The 52-week low price of Xencor Inc (XNCR) is $15.31.
The price-to-earnings (P/E) ratio of Xencor Inc (XNCR) is
The price-to-book (P/B) ratio of Xencor Inc (XNCR) is 2.42
The dividend yield of Xencor Inc (XNCR) is 0.00%
The market capitalization of Xencor Inc (XNCR) is $1.75B
The stock symbol (or ticker) of Xencor Inc is XNCR